EC95 of Remifentanil for Preventing Cough

Predicted EC95 of Effect-site Concentration of Remifentanil for Preventing Cough After Laryngomicrosurgery From Propofol Anesthesia

The investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (EC95) for preventing cough after laryngomicrosurgery from propofol anesthesia.

At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). Extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Inclusion Criteria:

• ASA I-II patients undergoing general anesthesia for laryngomicrosurgery

Exclusion Criteria:

• Anticipated difficult airway
• COPD, Asthma
• Recent URI (< 2 weeks)
• Severe cardiac, hepatic renal disease